Updated

Updated · Bloomberg · Jun 8

Novo Nordisk CEO Eyes 2 New Uses for Obesity Drugs in Longevity, Aesthetics

Updated

Updated · Bloomberg · Jun 8

Novo Nordisk CEO Eyes 2 New Uses for Obesity Drugs in Longevity, Aesthetics

3 articles · Updated · Bloomberg · Jun 8

Mike Doustdar said Novo Nordisk’s obesity franchise could expand beyond weight loss into two adjacent fields — longevity research and aesthetic medicine.
At the American Diabetes Association conference in New Orleans, Doustdar said the push reflects patient demand, adding that the company must stay “obsessed” with what patients want.
The comments suggest Novo is looking to widen the commercial and clinical reach of its blockbuster obesity drugs as competition intensifies across the fast-growing market.

Sources

Left50%

Right50%

Bloomberg2h ago

Novo Nordisk CEO Mike Doustdar Eyes Longevity, Aesthetics for Obesity Drugs

AD HOC NEWS1d ago

Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027

finance.biggo.com2h ago

Novo Nordisk Eyes Longevity and Aesthetics as Wegovy Pill Captures 80% New Users — BigGo Finance

Is Novo Nordisk's longevity venture a true medical frontier or a strategic gamble to outrun its competitors and looming patent cliffs?

With genes now predicting a drug's success, are we entering an era where DNA will dictate our weight loss prescriptions?

As blockbuster drugs pivot from treating sickness to enhancing life, will 'aging' soon become a treatable condition only for the wealthy?

Related Stories

Sources

7 total

Left50%

Right50%

Bloomberg2h ago

Novo Nordisk CEO Mike Doustdar Eyes Longevity, Aesthetics for Obesity Drugs

AD HOC NEWS1d ago

Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027

finance.biggo.com2h ago

Novo Nordisk Eyes Longevity and Aesthetics as Wegovy Pill Captures 80% New Users — BigGo Finance

Show all 7 sources

Related Stories